Redx is still liquidity constrained on AIM,” said Griffiths. “As a result, we believe our current market valuation is not reflective of our track record or future potential and is not ...

Redx is also eligible for tiered royalties of mid-single digit percentages, based on any future net sales. In the meantime Redx will continue to develop its lead cancer drug, RXC004, which is also ...